Personalized pharmacotherapy for Type 2 diabetes mellitus.
about
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.The methodology of glucose monitoring in type 2 diabetes mellitusComparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.
P2860
Personalized pharmacotherapy for Type 2 diabetes mellitus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@en
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@nl
type
label
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@en
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@nl
prefLabel
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@en
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@nl
P2860
P356
P1476
Personalized pharmacotherapy for Type 2 diabetes mellitus.
@en
P2093
Adrian Vella
Airani Sathananthan
P2860
P304
P356
10.2217/PME.09.3
P407
P577
2009-07-01T00:00:00Z